Biocon Limited has informed the Exchange regarding a press release dated Jun 24, 2025, titled "Biocon Biologics Collaborates with National Cancer Society MalaysiaRolls Out Patient Assistance Program to Expand Affordable Access to Biosimilars".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Biologics, a subsidiary of Biocon Limited, has signed an MoU with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Program aimed at improving affordable access to cancer biosimilars for underserved patients in Malaysia. The program will initially provide Trastuzumab, with Pegfilgrastim and Bevacizumab also part of Biocon's oncology portfolio included in the collaboration. The MoU was signed during the National Cancer Congress Malaysia 2025, witnessed by Malaysia's Health Minister. Biocon Biologics already has a track record in Malaysia, having served over 345,000 patients with diabetes biosimilars, and operates in 120+ countries with 9 commercialized biosimilars.
Positive sentiment for shareholders as it reinforces Biocon Biologics' international expansion in oncology biosimilars and strengthens its emerging markets presence in Malaysia. However, this is primarily a patient access/CSR initiative rather than a direct large-scale revenue deal, so immediate financial impact is likely limited while brand visibility and long-term market positioning get a boost.